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Esophageal adenocarcinoma (EA) is characterized by a strong male predominance. Sex
steroid hormones have been hypothesized to underlie this sex disparity, but no population-
based study to date has examined this potential association.
Methods
Using mass spectrometry and ELISA, we quantitated sex steroid hormones and sex hor-
mone binding globulin, respectively, in plasma from males– 172 EA cases and 185 con-
trols–within the Factors Influencing the Barrett/Adenocarcinoma Relationship (FINBAR)
Study, a case-control investigation conducted in Northern Ireland and Ireland. Multivariable
adjusted logistic regression was used to calculate odds ratios (ORs) and 95% confidence
intervals (CIs) for associations between circulating hormones and EA.
Results
Higher androgen:estrogen ratio metrics were associated with increased odds of EA (e.g.,
testosterone:estradiol ratio ORQ4 v. Q1 = 2.58, 95%CI = 1.23–5.43; Ptrend = 0.009). All estro-
gens and androgens were associated with significant decreased odds of EA. When
restricted to individuals with minimal to no decrease in body mass index, the size of associa-
tion for the androgen:estrogen ratio was not greatly altered.
Conclusions
This first study of sex steroid hormones and EA provides tentative evidence that androgen:
estrogen balance may be a factor related to EA. Replication of these findings in prospective
studies is needed to enhance confidence in the causality of this effect.
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Introduction
Esophageal adenocarcinoma (EA) is more common in men than women worldwide, with a
male-to-female ratio of approximately 4.4 [1]. However, the male-to-female ratio peaks
between 50 to 54 years and then decreases [2], suggesting an androgenic effect and perhaps
estrogenic protection. Additionally, established risk factors that vary in prevalence by sex, such
as smoking and obesity, cannot fully explain the male predominance [3, 4]. Thus, sex steroid
hormones have been proposed as a possible explanation of the sex disparity [5]. This hypothe-
sis is supported by sex steroid hormone involvement in the inflammatory process, including
associations between testosterone and inflammatory markers [6–9], sex steroid hormone
receptor protein expression—specifically estrogen receptor β—in esophageal cancer tissue [10,
11], and lower rates of EA among men with prostate cancer, who are likely to receive anti-
androgen therapies [12, 13]. Additionally, a small hospital-based study reported higher testos-
terone levels among EA cases (n = 25) than controls (n = 8) [14], and two studies of the EA
precursor metaplasia, Barrett’s esophagus (BE), reported positive associations for free andro-
gens [15, 16]. Thus, we investigated whether circulating sex steroid hormone concentrations
were associated with EA in the Factors Influencing the Barrett/Adenocarcinoma Relationship
(FINBAR) study–a population-based case-control study of EA and BE conducted in Northern
Ireland and the Republic of Ireland between 2002 and 2004 [17–36].
Materials and methods
Study population
The aim of the FINBAR study was to determine the stage along the esophageal inflammation-
metaplasia-adenocarcinoma sequence that potential risk factors for BE and EA exert their
effects [35]. To accomplish this, the study included individuals aged85 years with a histologi-
cally confirmed EA (N = 227) and3 cm of visible BE (n = 224). In situ cancers were excluded.
In Northern Ireland, cases were identified from electronic pathology records from all laborato-
ries in the province. In the Republic of Ireland, cases were identified from primary esophageal
cancer treatment centers. The association between sex steroid hormones and BE has previously
been reported [16]; therefore, only EA cases and controls are included in the current study.
Eligible controls were adults without a history of gastrointestinal cancer or BE (N = 260).
Controls were selected at random from the General Practice Master Index in Northern Ireland
and from four general practices in the Republic of Ireland and frequency-matched to cases on
sex and 5-year age group.
For the current study of circulating hormones, we restricted the study population to males
because there were too few females to provide adequate statistical power for a female-only
analysis.
Thus, 172 EA cases and 185 controls are included in the current study. The FINBAR study
was approved by the Research Ethics Committee of Queen’s University Belfast, the Clinical
Research Ethics Committee of Cork Teaching Hospitals, the Research Ethics Committee
Board of St. James’s Hospital, Dublin, and the National Institutes of Health Office of Human
Subjects Research.
Data and sample collection
Information on demographics and risk factors was obtained by a structured computerized
interview administered by trained interviewers. Anthropometric variables (i.e., height, weight,
waist, and hip circumference) were measured at the time of interview and recalled from
Association between circulating levels of sex steroid hormones and esophageal adenocarcinoma
PLOS ONE | https://doi.org/10.1371/journal.pone.0190325 January 17, 2018 2 / 13
Ireland. The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Abbreviations: ADT, androsterone; BE, Barrett’s
esophagus; CV, coefficient of variation; DHEA,
dehydroepiandrosterone; DHT,
dihydrotestosterone; EA, esophageal
adenocarcinoma; FINBAR, Factors Influencing the
Barrett/Adenocarcinoma Relationship; GERD,
gastroesophageal reflux disease; SHBG, sex
hormone binding globulin.
5-years prior to study enrollment. Written informed consent was obtained from each partici-
pant before interview.
At the time of interview, a 30 ml sample of peripheral venous blood (non-fasting) was
drawn, transported on ice, and then centrifuged within 2 hours for the majority of partici-
pants. Serum, plasma, and buffy coat were stored at −80˚C. Plasma samples from EDTA-
treated tubes were used for quantitation of circulating sex steroid hormones and sex hormone
binding globulin (SHBG).
Laboratory assays and measurements
All assays were performed in 2015 at the Pharmacogenomics Laboratory of Laval University,
Quebec, Canada. The plasma samples were never thawed prior to this study and have been
stored since processing at −80˚C. Prior studies have shown long-term stability of sex steroid
hormones at temperatures less than or equal to −20˚C [37–43]. Samples were quantitated for
dehydroepiandrosterone (DHEA), androstenediol, androstenedione, progesterone, testoster-
one, dihydrotestosterone (DHT), androsterone (ADT), estrone, and estradiol using gas chro-
matography–mass spectrometry [44]. In each of the nine batches, three low and three high
hormone concentration quality control replicates were included. All hormone coefficients of
variation (CVs) were less than 10% (range: 3.5–7.4%).
SHBG was quantitated using ELISA (Diagnostics Biochem Canada, Inc.). In each of the four-
teen batches, one low and one high concentration replicate were included and the CV was 8.8%.
In addition to individual hormones, we calculated parent estrogens (the sum of estrone and
estradiol), testosterone:parent estrogens ratio, testosterone:estradiol ratio, androstenedione:
estrone ratio, free estradiol [45], free testosterone [46], and free DHT [47]. Hormone levels
were categorized in quartiles, based on the distributions among the control participants.
Quantiles allowed examination of the associations without assumptions about the underlying
dose-response relationship. Tests of linear trend were performed based on the quartile-specific
medians of the hormone levels.
Statistical analysis
Unconditional logistic regression was used to calculate odds ratios (ORs) and corresponding
95% confidence intervals (CIs) for the associations between circulating hormones and EA
odds. Potential confounders were variables associated with EA and with at least one exposure.
These were entered into an age-adjusted multivariable stepwise logistic regression model
(entrance p-value = 0.05 and removal p-value = 0.10). Final adjusted models included age
(<54.1, 54.1–65.8, 65.9–72.2,72.3), education (<10, 10–12,13 years), smoking status
(ever, never), body mass index (BMI, <25.0, 25.0–29.9,30.0 kg/m2), frequent gastroesopha-
geal reflux disease (GERD) symptoms (yes, no; defined as heartburn or acid reflux occurring
weekly at least 5 years prior to the interview), and serologic Helicobacter pylori status (positive,
negative) [34]. We additionally tested alcohol consumption, physical activity, occupation,
waist-to-hip ratio, aspirin use, proton pump inhibitor use, and H2 receptor antagonist use, but
these did not meet the inclusion criteria and were not included in the final models. Addition-
ally, adjustment for age and BMI as continuous instead of categorical measures had negligible
effects on the analysis. As androgens and estrogens are known to exhibit circadian variation
[48], we also adjusted for blood draw time of day (as minutes and am/pm), and our results
were not substantially altered. Effect measure modification of the relationship between hor-
mones–modeled both as continuous and categorical–and EA by age, BMI, smoking, H. pylori,
GERD symptoms, waist-to-hip ratio, proton pump inhibitor use, H2 receptor antagonist use,
and geographic location was assessed using likelihood ratio tests [49]. The likelihood ratio tests
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were corrected for multiple comparisons using a false discovery rate [50]. After correction,
there were no effect-measure modifiers of the associations between hormones and EA.
All tests were two-sided. All analyses were conducted using SAS, version 9.3 (SAS Institute,
Cary, NC).
Sensitivity analysis
As the measured hormone levels could be affected by cachexia—or weight loss due to underly-
ing EA—we categorized the cases into three groups: 1) individuals without weight loss between
BMI reported 5-years prior to interview and the BMI measured at interview (i.e., BMI
change 0 kg/m2); among individuals with weight loss, we dichotomized BMI change at the
mean into 2) BMI change <-3.8 kg/m2 and 3) BMI change -3.8 to<0 kg/m2. This analysis was
conducted using polytomous logistic regression. Sample size was limited; thus, we dichoto-
mized the hormone levels. To further examine the potential residual confounding by age, we
examined continuous hormone variables, which were standardized to half the value of the
interquartile range, and adjusted for continuous age.
Results
Descriptive characteristics of controls and EA cases are presented in S1 Table. Significant dif-
ferences were noted for GERD symptoms (20% controls v. 48% EA cases), H. pylori positivity
(63% v. 52%), manual occupation (51% v. 63%), ever-smoking (64% v. 84%), and education
(11.7 v. 10.6 years). Additionally, significant differences in BMI were noted for both self-
reported BMI 5-years prior to enrollment or diagnosis (27.2 v. 28.6 kg/m2) and measured at
study enrollment (27.9 v. 26.3 kg/m2).
As shown in Table 1, most of the individual hormones had higher measured concentrations in
the controls than in the EA cases. For example, testosterone (12.07 v. 10.83 nmol/L, respectively)
Table 1. Mean circulating metabolite concentrations among esophageal adenocarcinoma cases and controls, in the FINBAR Study: 2002–2004.
Controls Esophageal Adenocarcinoma Cases P-valuea
Hormone N Median Interquartile Range N Median Interquartile Range
DHEA, nmol/L 185 5.13 3.36–8.18 169 3.68 1.87–5.55 <0.0001
Androstenediol, pmol/L 183 1764.39 1315.76–2494.35 164 1286.03 848.78–1913.04 <0.0001
Androstenedione, nmol/L 185 2.72 2.03–3.39 171 2.34 1.68–3.28 0.06
Testosterone, nmol/L 184 12.07 9.67–15.20 170 10.83 7.52–14.77 0.01
DHT, pmol/L 184 1008.55 751.13–1372.98 171 746.69 548.68–1193.90 <0.0001
ADT, pmol/L 174 592.55 409.10–754.82 143 466.67 315.11–643.47 <0.0001
Estrone, pmol/L 185 104.23 81.11–129.60 165 89.99 65.21–126.75 0.0009
Estradiol, pmol/L 185 67.33 55.29–82.60 170 50.54 37.48–66.49 <0.0001
Progesterone, nmol/L 90 0.23 0.19–0.36 91 0.26 0.20–0.34 0.3
SHBG, nmol/L 184 53.70 39.50–69.35 172 71.10 48.65–100.90 <0.0001
Parent estrogens, pmol/L 185 175.22 142.98–210.75 165 139.37 106.03–196.09 <0.0001
Testosterone: Parent estrogens ratio 184 68.78 54.55–87.32 165 78.88 52.38–102.22 0.05
Androstenedione: Estrone ratio 185 24.49 20.59–31.03 165 26.16 18.98–37.99 0.2
Testosterone: Estradiol ratio 184 177.92 140.11–221.56 170 209.59 157.47–279.48 0.0002
Free testosterone, nmol/L 183 0.18 0.14–0.22 170 0.13 0.09–0.17 <0.0001
Free DHT, pmol/L 183 16.35 11.99–20.41 170 10.21 6.50–13.93 <0.0001
Free estradiol, pmol/L 184 1.51 1.27–1.85 170 0.99 0.73–1.42 <0.0001
aWilcoxon-Mann-Whitney test comparing the medians of cases and controls.
https://doi.org/10.1371/journal.pone.0190325.t001
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and estradiol (67.33 v. 50.54 pmol/L) concentrations were both higher in controls than cases.
However, the androgen:estrogen ratio metrics were lower in controls compared to cases (e.g., tes-
tosterone:estradiol ratio 177.92 v. 209.59).
Individual sex steroid hormones, and calculated free estradiol, free testosterone, and free
DHT, were associated with significantly decreased EA odds (Table 2). However, SHBG and
the androgen:estrogen ratio metrics–particularly testosterone:estradiol–were associated with
an increased EA odds. Comparing quartile 4 versus 1, SHBG was associated with 2.3-times the
odds of EA (OR = 2.30, 95% CI = 1.10–4.80; Ptrend = 0.01), and the testosterone:estradiol ratio
was associated with 2.6-times the odds (OR = 2.58, 95% CI = 1.23–5.43; Ptrend = 0.009). Adjust-
ment for covariates had little effect on the estimates, as observed in the unadjusted results (S2
Table).
When we examined the cases by BMI change, the androgen:estrogen ratio metrics were still
associated with an increased odds of EA among individuals with little to no BMI change dur-
ing the 5 years preceding interview. Comparing individuals withmedian versus < median,
testosterone:estradiol ratio was associated with 1.4 to 2.6-times the odds of EA among individ-
uals with little to no BMI change (OR = 1.35, 95% CI = 0.54–3.39; Ptrend = 0.3 among EA cases
with a BMI change0 kg/m2 and OR = 2.61, 95% CI = 1.27–5.38; Ptrend = 0.0005 among indi-
viduals with a BMI change of -3.8 to<0 kg/m2) (S3 Table). Additional adjustment of the con-
tinuous hormones and SHBG for continuous age did not substantially alter the results (S4
Table).
Discussion
This is the first population-based study to examine associations between circulating sex steroid
hormones and EA and provides tentative evidence that androgen:estrogen balance may be a fac-
tor related to EA. In our analysis, a high ratio of androgens to estrogens–particularly testoster-
one:estradiol ratio–was more common in EA patients than controls, including after restriction
to cases without weight loss in the previous 5 years. The highest quartile ratio of testosterone:
estradiol was associated with a 2.4-times increased odds of EA, while androstenedione:estrone
and testosterone:parent estrogens ratios were associated with a non-significant 1.6-times odds.
However, many of the individual hormone metrics assessed were inversely associated with EA.
Deciphering the extent to which these associations are due to reverse causation will require pro-
spective studies with prediagnostic hormone quantitation.
In older men, obesity is strongly linked to SHBG and influences levels of circulating sex
hormones. Specifically, higher BMI is associated with lower levels of DHEA, testosterone, and
SHBG and higher levels of estrogens [51]. In our main analysis, only 23% of the cases did not
experience weight loss during the 5-years prior to cancer diagnosis. Cancer patients often pres-
ent with cachexia, which is associated with hypogonadism. Thus, we were concerned that our
findings could be a consequence of the cancer itself. Indeed, studies suggest testosterone levels
are lower and SHBG higher in male cancer cases compared to age-matched healthy men [52–
54]. As a sensitivity analysis, we examined cases by BMI changes in the 5-years prior to study
entry. The results showed that SHBG was associated with increased odds of EA among individ-
uals with the most extreme BMI loss (i.e., <-3.8 kg/m2), but not among individuals with little
to no BMI loss. Among individuals with little to no BMI change, the ratios of androgens:estro-
gens were associated with increased odds of EA, but not among individuals with extreme BMI
loss. However, cautious interpretation is warranted, as these were post hoc analyses that used a
proxy (i.e., BMI) of cancer’s metabolic effects.
While it has long been hypothesized that sex steroid hormones may underlie the sex dispar-
ities in EA pathogenesis [5], no population-based study to date has examined circulating sex
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Table 2. Adjusteda odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between circulating metabolite concentrations and esophageal adeno-
carcinoma incidence, in the FINBAR Study: 2002–2004.
Hormone Control (n) Esophageal Adeno. (n) OR 95% CI
DHEA, nmol/L
<3.36 45 70 Referent
3.36 to <5.13 38 40 0.91 (0.46, 1.80)
5.13 to <8.18 46 29 0.43 (0.21, 0.90)
8.18 43 16 0.32 (0.14, 0.76)
P trendb 0.003
Androstenediol, pmol/L
<1315.76 41 79 Referent
1315.76 to <1764.39 42 34 0.41 (0.21, 0.80)
1764.39 to <2494.35 44 27 0.33 (0.16, 0.68)
2494.35 43 12 0.13 (0.05, 0.30)
P trendb <0.0001
Androstenedione, nmol/L
<2.03 45 57 Referent
2.03 to <2.72 42 39 0.96 (0.48, 1.92)
2.72 to <3.39 41 26 0.57 (0.27, 1.19)
3.39 44 35 0.65 (0.32, 1.31)
P trendb 0.1
Testosterone, nmol/L
<9.67 42 66 Referent
9.67 to <12.07 45 28 0.54 (0.27, 1.07)
12.07 to <15.20 42 30 0.45 (0.22, 0.92)
15.20 42 32 0.50 (0.25, 1.01)
P trendb 0.05
DHT, pmol/L
<751.13 42 80 Referent
751.13 to <1008.55 43 29 0.39 (0.19, 0.78)
1008.55 to <1372.98 42 21 0.23 (0.11, 0.50)
1372.98 44 27 0.23 (0.11, 0.49)
P trendb <0.0001
ADT, pmol/L
<409.10 38 51 Referent
409.10 to <592.55 43 44 0.73 (0.37, 1.44)
592.55 to <754.82 42 21 0.40 (0.19, 0.87)
754.82 41 15 0.28 (0.12, 0.64)
P trendb 0.0008
Estrone, pmol/L
<81.11 41 72 Referent
81.11 to <104.23 45 31 0.34 (0.17, 0.68)
104.23 to <129.60 42 19 0.24 (0.11, 0.52)
129.60 44 29 0.36 (0.18, 0.72)
P trendb 0.003
Estradiol, pmol/L
<55.29 46 97 Referent
55.29 to <67.33 42 21 0.25 (0.12, 0.52)
67.33 to <82.60 41 16 0.20 (0.09, 0.44)
(Continued)
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Table 2. (Continued)
Hormone Control (n) Esophageal Adeno. (n) OR 95% CI
82.60 43 22 0.25 (0.12, 0.51)
P trendb <0.0001
Progesterone, nmol/Lc
<0.15 86 74 Referent
0.15 to <0.20 29 21 0.74 (0.35, 1.54)
0.20 to <0.29 29 33 1.58 (0.80, 3.14)
0.29 28 30 1.00 (0.49, 2.01)
P trendd 0.9
SHBG, nmol/L
<39.50 43 27 Referent
39.50 to <53.70 42 28 0.97 (0.44, 2.13)
53.70 to <69.35 44 23 0.64 (0.28, 1.44)
69.35 42 80 2.30 (1.10, 4.80)
P trendb 0.01
Parent estrogens, pmol/L
<142.98 43 85 Referent
142.98 to <175.22 43 23 0.29 (0.14, 0.61)
175.22 to <210.75 42 19 0.22 (0.10, 0.47)
210.75 44 24 0.26 (0.13, 0.54)
P trendb <0.0001
Testosterone: Parent estrogens ratio
<54.55 45 35 Referent
54.55 to <68.78 39 23 0.91 (0.42, 2.00)
68.78 to <87.32 44 31 0.93 (0.43, 1.99)
87.32 43 62 2.06 (1.00, 4.24)
P trendb 0.03
Androstenedione: Estrone ratio
<20.59 41 41 Referent
20.59 to <24.49 43 18 0.54 (0.24, 1.20)
24.49 to <31.03 44 31 0.92 (0.44, 1.92)
31.03 44 61 1.56 (0.76, 3.22)
P trendb 0.1
Testosterone: Estradiol ratio
<140.11 44 28 Referent
140.11 to <177.92 40 28 1.31 (0.59, 2.91)
177.92 to <221.56 44 26 1.10 (0.49, 2.48)
221.56 43 74 2.58 (1.23, 5.43)
P trendb 0.009
Free testosterone, nmol/L
<0.14 41 91 Referent
0.14 to <0.18 45 28 0.31 (0.16, 0.61)
0.18 to <0.22 42 24 0.26 (0.12, 0.53)
0.22 42 13 0.16 (0.07, 0.37)
P trendb <0.0001
Free DHT, pmol/L
<11.99 42 101 Referent
11.99 to <16.35 41 32 0.24 (0.12, 0.49)
(Continued)
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steroid hormones and EA. One small hospital-based study (n = 25 cases) that examined the
association between fasting serum testosterone reported that EA cases had significantly higher
testosterone concentrations compared with eight control subjects. However, post-esophagect-
omy testosterone levels in cases decreased to levels similar to controls, leading the authors to
conclude that the cancer was causing higher circulating testosterone concentrations [14].
While stage information and treatment status was not uniformly collected in the current
study, blood samples were collected prior to treatment for the majority of participants. There-
fore, changes in testosterone levels post-treatment are unlikely to completely explain the
inverse association between testosterone and EA in our main analysis.
Additionally, BE has been examined in relation to circulating sex steroid hormones in two
studies–one from a U.S. military medical center and one from the FINBAR Study. Both studies
determined that free androgens were associated with increased odds of BE, although this was
limited to participants with a high waist-to-hip ratio in the FINBAR Study [15, 16]. Thus, free
androgens may be important in the development of BE–possibly by delaying wound healing
and allowing more time for metaplasia to develop–while the balance of androgens and estro-
gens is tentatively inferred from this study to be a factor for progression to invasive cancer.
In vitro studies of esophageal squamous cell carcinoma [55] and adenocarcinoma [56] have
shown that administration of estradiol decreases cell growth. One of these studies further
examined the effects of estradiol and DHT administration on EA tumors in mice and reported
that estradiol injections resulted in a high estradiol:DHT ratio and significant inhibition of
tumor growth [55]. This indirectly further supports that the androgen:estrogen balance may
be important for EA development, whereby higher levels of androgens relative to estrogens
may favor cellular proliferation and tumor growth.
A potential limitation of the current study is that the plasma for cases was collected at time
of interview. While the esophagus is not an endocrine gland, there is the possibility that circu-
lating hormone concentrations could be affected by tumor growth and reverse causation could
be contributing to these findings [14]. Additionally, age and chronic disease status may alter
hormone and SHBG levels. We adjusted the models for age and GERD, which has been sug-
gested to be associated with altered hormone levels [57], but there still may be residual con-
founding. There is also a potential in this study for recall bias, or differential recall between
Table 2. (Continued)
Hormone Control (n) Esophageal Adeno. (n) OR 95% CI
16.35 to <20.41 44 12 0.09 (0.04, 0.21)
20.41 43 11 0.07 (0.03, 0.18)
P trendb <0.0001
Free estradiol, pmol/L
<1.27 44 106 Referent
1.27 to <1.51 41 21 0.24 (0.12, 0.50)
1.51 to <1.85 44 16 0.20 (0.09, 0.42)
1.85 42 13 0.15 (0.07, 0.34)
P trendb <0.0001
aLogistic regression models were adjusted for age at interview (quartiles), education (<10, 10–12, 13–20 years), smoking (ever/never), BMI at interview (<25, 25–<30,
30 kg/m2), gastroesophageal reflux disease symptoms (yes/no), and H. pylori seropositivity (yes/no).
bTests of linear trend were calculated by assigning the median of each quartile as scores.
cProgesterone values below the LOD form the referent with the subsequent three categories based on tertiles of the observed population distribution.
dTest of linear trend for progesterone was calculated by assigning the categorical groups as scores.
https://doi.org/10.1371/journal.pone.0190325.t002
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cases and controls, particularly for weight 5 years prior to study interview. A strength of the
current study is that the FINBAR Study was designed specifically to examine risk factors for
EA–such as GERD and H. pylori, and we were able to adjust for these. The current study also
used robust quantitative technology for sex steroid hormone measurement.
In summary, this study provides tentative evidence that the balance of androgens to estro-
gens may be important in the development of EA. However, the large number of inverse asso-
ciations detected make the possibility of reverse causation more likely and underscore the
need for a cautious interpretation. Future studies need to be conducted using prospectively
collected blood to provide additional confidence that these associations between sex steroid
hormones and EA represent causal effects and not effects of cachexia.
Supporting information
S1 Table. Distribution of characteristics among control participants and esophageal ade-
nocarcinoma cases, in the FINBAR Study2002–2004. aP values based on t-test for continu-
ous variables and χ2 test for categorical variables. bDefined as at least 50 times per year or
about once a week. cDefined as at least once weekly for 6 months or more.
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